Ability of an antibiogram to predict Pseudomonas aeruginosa susceptibility to targeted antimicrobials based on hospital day of isolation

Infection Control and Hospital Epidemiology

Volumn 33, Issue 6, 2012, Pages 589-593

  Anderson, Deverick J ^a   Miller, Becky ^b   Marfatia, Ruchit ^c   Drew, Richard ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c University College of Pharmacy and Health Science   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; COHORT ANALYSIS; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; COHORT STUDIES; CROSS INFECTION; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LOGISTIC MODELS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84860663578     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/665721     Document Type: Article

References (20)

1. Wisplinghoff H, Bischoff T, Tallent S, Seifert H, Wenzel R, Edmond M. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317.
2. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis 1997; 24:1068-1078.
3. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885-888.
4. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999;27:887-892.
5. Diekema DJ, Pfaller MA, Jones RN, et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 1999;29: 595-607.
6. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004;48:4606-4610.
7. Kang C, Kim S, Park W. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005;49:760-766.
8. Marschall J, Agniel D, Fraser V, Doherty J, Warren D. Gramnegative bacteraemia in non-ICU patients: factors associated with inadequate antibiotic therapy and impact on outcomes. J Antimicrob Chemother 2008;61:1376-1383.
9. Dellit T, Owens R, McGowan J Jr. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44: 159-177.
10. Pakyz A. The utility of hospital antibiograms as tools for guiding empiric therapy and tracking resistance insights from the society of infectious diseases pharmacists. Pharmacotherapy 2007;27: 1306-1312.
11. Banter C, Alcazar G, Franco D. Are laboratory-based antibiograms reliable to guide the selection of empirical antimicrobial treatment in patients with hospital-acquired infections? J Antimicrob Chemother 2007;59:140-143.
12. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43(6):1379-1382.
13. Lodise TP, Miller CD, Graves J, et al. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. Antimicrob Agents Chemother 2007;51(2):417-422.
14. Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, Lautenbach E. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 2006;119(6):e519-e525.
15. Clinical and Laboratory Standards Institute (CLSI). Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters: Approved Guideline-Third Edition. Wayne, PA: CLSI; 2008. CLSI document M23-A3.
16. Mizuta M, Linkin DR, Nachamkin I, et al. Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: potential role of a combination antibiogram. Infect Control Hosp Epidemiol 2006;27: 413-415.
17. Bryce EA, Smith JA. Focused microbiological surveillance and gram-negative beta-lactamase-mediated resistance in an intensive care unit. Infect Control Hosp Epidemiol 1995;16:331-334.
18. Stratton CW, Ratner H, Johnston PE, Schaffner W. Focused microbiologic surveillance by specific hospital unit as a sensitive means of defining antimicrobial resistance problems. Diagn Microbiol Infect Dis 1992;15:11S-18S.
19. Binkley S, Fishman NO, LaRosa LA, et al. Comparison of unitspecific and hospital-wide antibiograms: potential implications for selection of empirical antimicrobial therapy. Infect Control Hosp Epidemiol 2006;27:682-687.
20. El Amari EB, Chamot E, Auckenthaler R, Pechere JC, Van DC. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001;33:1859-1864.